We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $1.8B
1-Year Est. Return 36.16%
This Fund
S&P 500
This Quarter Est. Return
+9.21%
1 Year Est. Return
+36.16%
3 Year Est. Return
+116.66%
5 Year Est. Return
+140.56%
10 Year Est. Return
+771.9%
AUM
$2.75B
AUM Growth
+$188M
Cap. Flow
+$19.8M
Cap. Flow %
0.72%
Top 10 Hldgs %
19.69%
Holding
327
New
32
Increased
100
Reduced
149
Closed
29

Sector Composition

Rank Sector Weight
1 Healthcare 22.97%
2 Industrials 19.87%
3 Technology 17.13%
4 Consumer Discretionary 9.66%
5 Communication Services 7.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BSTC
101
DELISTED
BioSpecifics Technologies Corp.
BSTC
$9.16M 0.33%
204,183
+42,429
+26% +$1.82M
OPTN
102
DELISTED
OptiNose
OPTN
$9.05M 0.33%
+21,557
New +$7.27M
TSCO icon
103
Tractor Supply
TSCO
$17.9B
$8.91M 0.32%
582,215
+238,405
+69% +$3.31M
TREX icon
104
Trex
TREX
$4.93B
$8.8M 0.32%
281,072
-3,108
-1% -$90.1K
CVGW
105
DELISTED
Calavo Growers
CVGW
$8.75M 0.32%
90,999
-164,888
-64% -$15.3M
SIX
106
DELISTED
Six Flags Entertainment Corp.
SIX
$8.69M 0.32%
123,989
+48,589
+64% +$3.17M
LOPE icon
107
Grand Canyon Education
LOPE
$3.88B
$8.65M 0.31%
77,497
+2,296
+3% +$252K
KERX
108
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$8.56M 0.31%
2,278,007
+361,533
+19% +$1.76M
ACRS icon
109
Aclaris Therapeutics
ACRS
$851M
$7.97M 0.29%
399,342
+187,545
+89% +$3.47M
MED icon
110
Medifast
MED
$136M
$7.6M 0.28%
47,467
-6,686
-12% -$855K
CLVS
111
DELISTED
Clovis Oncology, Inc.
CLVS
$7.01M 0.25%
154,115
+6,036
+4% +$294K
INSM icon
112
Insmed
INSM
$28.7B
$6.7M 0.24%
283,184
+21,472
+8% +$553K
NNBR icon
113
NN Inc
NNBR
$298M
$6.64M 0.24%
351,369
-15,568
-4% -$335K
MIXT
114
DELISTED
MIX TELEMATICS LIMITED
MIXT
$6.34M 0.23%
357,619
-26,623
-7% -$476K
JAZZ icon
115
Jazz Pharmaceuticals
JAZZ
$16.7B
$6.11M 0.22%
35,487
+3,485
+11% +$570K
PCOM
116
DELISTED
Points.com Inc. Common Shares
PCOM
$5.91M 0.21%
358,762
+7,666
+2% +$97.2K
AAP icon
117
Advance Auto Parts
AAP
$3.49B
$5.84M 0.21%
43,026
+7,564
+21% +$919K
ESL
118
DELISTED
Esterline Technologies
ESL
$5.77M 0.21%
78,143
+3,407
+5% +$252K
TDG icon
119
TransDigm Group
TDG
$69.8B
$5.73M 0.21%
16,591
-4,800
-22% -$1.58M
WLDN icon
120
Willdan Group
WLDN
$1.11B
$5.34M 0.19%
172,403
+141,998
+467% +$4.1M
CSGP icon
121
CoStar Group
CSGP
$12B
$5.23M 0.19%
126,670
+21,710
+21% +$836K
PII icon
122
Polaris
PII
$3.99B
$5.06M 0.18%
41,392
+7,012
+20% +$820K
CNTY icon
123
Century Casinos
CNTY
$33.5M
$4.9M 0.18%
560,009
-2,616
-0.5% -$21.7K
BMRN icon
124
BioMarin Pharmaceuticals
BMRN
$11.9B
$4.83M 0.18%
51,274
+8,913
+21% +$781K
FC icon
125
Franklin Covey
FC
$242M
$4.27M 0.16%
174,034
-1,077
-0.6% -$29K

Similar funds

Rice Hall James & Associates's Q2 2018 Portfolio in Review

As of Q2 2018, Rice Hall James & Associates held 327 positions worth $2.75B, up 7.3% from $2.56B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Rice Hall James & Associates's Q2 2018 filing shows 32 new, 100 increased, 149 reduced and 29 closed positions. Its largest new stake was DIPLOMAT PHARMACY, INC.: 818,939 shares worth $20.9M. The largest sale was Supernus Pharmaceuticals, an estimated $25.9M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 23% a quarter earlier, followed by Industrials and Technology.

  • Rice Hall James & Associates's largest Q2 2018 buy was DIPLOMAT PHARMACY, INC.: 818,939 shares worth $20.9M.
  • Rice Hall James & Associates added most to Apogee Enterprises in Q2 2018, an estimated $15.9M increase.
  • Rice Hall James & Associates's biggest Q2 2018 reduction was Supernus Pharmaceuticals, cutting an estimated $25.9M.
  • Rice Hall James & Associates fully exited Viasat in Q2 2018, selling an estimated $17M.
  • Rice Hall James & Associates's ten largest holdings make up 20% of its $2.75B portfolio in Q2 2018.
  • Rice Hall James & Associates opened 32 new positions and closed 29 in Q2 2018.
  • Rice Hall James & Associates's portfolio value rose 7.3% quarter-over-quarter to $2.75B.

Based on Rice Hall James & Associates's 13F filing for Q2 2018, filed 2 Aug 2018.